Genmab A/S (GNMSF)
OTCMKTS
· Delayed Price · Currency is USD
224.30
+6.17 (2.83%)
Jun 11, 2025, 12:39 PM EDT
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
| Total Royalties | 2.64B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Royalties Growth | 25.88% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Reimbursement | 126.55M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Reimbursement Growth | -1.06% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Milestone | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Milestone Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| License | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| DARZALEX Royalties | 2.11B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| DARZALEX Royalties Growth | 23.73% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Kesimpta Royalties | 346.37M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Kesimpta Royalties Growth | 42.83% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| TEPEZZA Royalties | 105.02M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| TEPEZZA Royalties Growth | 0.71% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Product Royalties | 77.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Product Royalties Growth | 75.58% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Collaboration | 64.83M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Collaboration Growth | 32.49% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Net Product Sales | 279.10M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Net Product Sales Growth | 157.61% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| J&J | 2.20B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| J&J Growth | 22.42% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Novartis | 430.23M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Novartis Growth | 75.94% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| BioNTech | 108.56M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| BioNTech Growth | -7.14% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pfizer | 78.48M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pfizer Growth | 34.51% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Collaboration Partner | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Roche | 105.60M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Roche Growth | 1.27% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| AbbVie | 9.43M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| AbbVie Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2011 - 2019 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2011 - 2019 |
| Denmark |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Denmark Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Japan |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Japan Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|